Log In
Print
BCIQ
Print
Print this Print this
 

ISIS 416858, ISIS-FXIRx

Also known as: Factor XI antisense inhibitor

  Manage Alerts
Collapse Summary General Information
Company Isis Pharmaceuticals Inc.
DescriptionFactor XI antisense inhibitor
Molecular Target Factor XI
Mechanism of ActionAntisense therapy
Therapeutic ModalityNucleic acid: Linear RNA: Antisense
Latest Stage of DevelopmentPhase II
Standard IndicationBlock coagulation
Indication DetailsPrevent venous thromboembolism (VTE) in patients undergoing total knee replacement surgery
Regulatory Designation
Partner Bayer AG

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$475.0M

$100.0M

$375.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today